KYMR Q1 2023 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-1.6% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$45M-478.8% margin

Net Income

-$41M-432.4% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

-41.3%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$48M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$614M

Total Liabilities

$152M

Stockholders' Equity

$462M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$10M	-1.6%
Gross Profit	$9M	$10M	-1.6%
Operating Income	-$45M	-$37M	-22.7%
Net Income	-$41M	-$37M	-11.6%